Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.02.001Source: DataRank Database

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2020). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access27 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 2.13)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Vincent A. LoRe,Anthony R. Mato ORCID,Elise A. Chong ORCID,Jacqueline C. Barrientos ORCID,James N. Gerson ORCID

Live enrichment

PubMed:32197990 PMC:PMC7305967 OpenAlex:https://openalex.org/W3007652109

Conquer Cancer Foundation

Grant: 15032

National Institutes of Health

Grant: T32 GM075766-11

NIGMS NIH HHS

Grant: T32 GM075766

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2T32GM075766-16

Clinical Pharmacoepidemiology Training Grant

AstraZeneca

DTRM

Genentech

Acerta

Johnson & Johnson

Merck

Novartis

Seattle Genetics

TG Therapeutics

Gilead

Pharmacyclics

Abbvie

Portola

Regeneron

BMS

Celgene

FWCI

2.13

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7305967

publisherhttps://api.elsevier.com/content/article/PII:S2152265020300665?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265020300665?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2020.02.001

Fields of Study

Chronic Lymphocytic Leukemia ResearchPhagocytosis and Immune RegulationChronic Myeloid Leukemia Treatments03 medical and health sciences0302 clinical medicine

MeSH Terms

AdenineAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPiperidinesRetrospective StudiesCohort StudiesLeukemia, Lymphocytic, Chronic, B-CellIncidenceTreatment OutcomeMyalgia

Keywords

IbrutinibMedicineChronic lymphocytic leukemiaInternal medicineChemoimmunotherapyCohortOncologyLeukemiaToxicityMusculoskeletalArthralgiasAdultAged, 80 and overMaleAdenineIncidenceMyalgiaMiddle AgedLeukemia, Lymphocytic, Chronic, B-CellCohort StudiesTreatment OutcomePiperidinesHumansFemaleAgedRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being